Evidence map›Paper›PMID 39227528›Full record

ArticleReproductive sciences (Thousand Oaks, Calif.)2024

Novel Biomarkers: Soluble Urokinase-Type Plasminogen Activator Receptor and Procalcitonin- and Histological Chorioamnionitis after Preterm Premature Rupture of Membranes.

Kati Jalkanen, Anita Virtanen, Janne Aittoniemi, Heidi Flinck, Sinikka Ampuja, Heini Huhtala, Kati Tihtonen

Abstract read
In one paragraph

Article in Reproductive sciences (Thousand Oaks, Calif.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kati JalkanenDepartment of Obstetric and Gynecology, Tampere University Hospital, Elämänaukio, Kuntokatu 2, Tampere, 33520, Finland. kati.jalkanen@pirha.fi.ORCID 0009-0009-4418-1716
Anita VirtanenDepartment of Obstetric and Gynecology, Tampere University Hospital, Elämänaukio, Kuntokatu 2, Tampere, 33520, Finland.
Janne AittoniemiDepartment of Clinical Microbiology, Fimlab Laboratories, Tampere, Finland.
Heidi FlinckDepartment of Clinical Microbiology, Fimlab Laboratories, Tampere, Finland.
Sinikka AmpujaDepartment of Pathology, Tampere University Hospital, Tampere, Finland.
Heini HuhtalaFaculty of Social Sciences, Tampere University, Tampere, Finland.
Kati TihtonenDepartment of Obstetric and Gynecology, Tampere University Hospital, Elämänaukio, Kuntokatu 2, Tampere, 33520, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fetal inflammatory response syndrome or infection after preterm premature rupture of membranes (PPROM) increases neonatal morbidity in preterm deliveries. Biochemical markers from the amniotic fluid (AF) have been used to evaluate possible intra-amniotic infection during the asymptomatic phase after PPROM. This study aimed to describe whether soluble urokinase-type plasminogen activator receptor (suPAR) or procalcitonin (PCT) from AF or maternal sera could reveal fetal inflammatory response or infection after PPROM. AF and maternal serum samples were collected weekly after PPROM (23

Indexed as

Amniotic FluidBiomarkersChorioamnionitisPremature Rupture of Fetal MembranesProcalcitoninReceptors, Urokinase Plasminogen ActivatorAdultFemaleHumansInterleukin-6PlacentaPregnancyBiomarkersInterleukin-6PLAUR protein, humanProcalcitoninReceptors, Urokinase Plasminogen ActivatorAmniotic fluidHistological chorioamnionitisPreterm premature rupture of membranesProcalcitoninSoluble urokinase-type plasminogen activator receptor

Identifiers

PMID39227528
PMCPMC11438667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.